Search hospitals > Maryland > Bethesda

National Cancer Institute (NCI)

Claim this profile
Bethesda, Maryland 20814
Global Leader in Cancer
Global Leader in Pancreatic Cancer
Conducts research for Breast Cancer
Conducts research for Melanoma
Conducts research for Tumors
296 reported clinical trials
11 medical researchers
Photo of National Cancer Institute (NCI) in BethesdaPhoto of National Cancer Institute (NCI) in BethesdaPhoto of National Cancer Institute (NCI) in Bethesda

Summary

National Cancer Institute (NCI) is a medical facility located in Bethesda, Maryland. This center is recognized for care of Cancer, Pancreatic Cancer, Breast Cancer, Melanoma, Tumors and other specialties. National Cancer Institute (NCI) is involved with conducting 296 clinical trials across 394 conditions. There are 11 research doctors associated with this hospital, such as A P. Chen, Nirali N. Shah, John Glod, MD, and Deborah Citrin, MD.

Area of expertise

1Cancer
Global Leader
National Cancer Institute (NCI) has run 76 trials for Cancer. Some of their research focus areas include:
Stage IV
EWSR1/ATF1 positive
EWSR1/CREB1 positive
2Pancreatic Cancer
Global Leader
National Cancer Institute (NCI) has run 36 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
BRCA positive

Top PIs

Clinical Trials running at National Cancer Institute (NCI)

Cancer
Skin Cancer
Melanoma
Bladder Cancer
Small Cell Lung Cancer
Kidney Cancer
Hairy Cell Leukemia
Peripheral Nerve Sheath Tumor
Lung Cancer
Solid Tumors
Image of trial facility.

GM T Cell Therapy Long-Term Follow-Up

for Cancer

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Recruiting1 award Phase 2 & 3
Image of trial facility.

ANK-101

for Cancer

This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy. The study will be conducted in three parts; in Part 1, participants with superficial lesions will receive ANK-101 as a single agent; in Part 2, participants with visceral lesions will receive ANK-101 as a single agent; and in Part 3, participants with cutaneous squamous cell carcinoma (CSCC) will receive ANK-101 in combination with cemiplimab.
Recruiting1 award Phase 1
Image of trial facility.

Olaparib

for Bladder Cancer

This trial studies how well olaparib works in patients with advanced bladder and other genitourinary cancers that have DNA-repair defects. Olaparib is a drug that stops cancer cells from fixing their damaged DNA, which can help to stop the cancer from growing. The trial targets patients whose cancers have spread and are not responsive to standard treatments.
Recruiting1 award Phase 220 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at National Cancer Institute (NCI)?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security